One of the mTOR complexes, mTORC1, which is frequently impaired in certain cancers, has been shown to be more sensitive to treatment with sirolimus than mTORC2, making sirolimus a potential anticancer treatment as well [174]. This evidence concerns the gene MTOR and cancer.